Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash & Current Investments: 2014-2024

Historic Cash & Current Investments for KalVista Pharmaceuticals (KALV) over the last 8 years, with Dec 2024 value amounting to $268.3 million.

  • KalVista Pharmaceuticals' Cash & Current Investments was N/A to $268.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $788.8 million, marking a year-over-year change of. This contributed to the annual value of $210.4 million for FY2024, which is N/A change from last year.
  • As of Q4 2024, KalVista Pharmaceuticals' Cash & Current Investments stood at $268.3 million, which was up 97.64% from $135.8 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Cash & Current Investments registered a high of $268.3 million during Q4 2024, and its lowest value of $50.3 million during Q1 2021.
  • Over the past 2 years, KalVista Pharmaceuticals' median Cash & Current Investments value was $135.8 million (recorded in 2024), while the average stood at $155.8 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 40.22% in 2020, then soared by 41.39% in 2024.
  • Quarterly analysis of 4 years shows KalVista Pharmaceuticals' Cash & Current Investments stood at $55.9 million in 2020, then plummeted by 37.56% to $50.3 million in 2021, then reached $103.2 million in 2023, then spiked by 31.60% to $268.3 million in 2024.
  • Its last three reported values are $268.3 million in Q4 2024, $135.8 million for Q4 2024, and $174.3 million during Q3 2024.